Advertisement
Table 1 Patient characteristics in study groups at inclusion in the study (before) and after 12 weeks of treatment (after) with empagliflozin 25 mg daily (EMPA), metformin 2000 mg daily (MET), empagliflozin/metformin (EMPA/MET) or placebo (PLACEBO)
| PLACEBO | EMPA | MET | EMPA/MET | |||||
|---|---|---|---|---|---|---|---|---|
| Before | After | Before | After | Before | After | Before | After | |
| Average age (years) | 43.1 ± 2.1 | 46.0 ± 2.3 | 46.4 ± 3.9 | 43.3 ± 2.6 | ||||
| Duration of diabetes (years) | 22.2 ± 3.8 | 22.5 ± 3.7 | 23.2 ± 4.8 | 22.3 ± 3.2 | ||||
| HbA1c (%) | 7.8 ± 0.2 | 7.7 ± 0.3 | 7.8 ± 0.1 | 7.4 ± 0.1 | 7.9 ± 0.2 | 7.7 ± 0.3 | 7.8 ± 0.2 | 7.2 ± 0.2* |
| Systolic BP (mmHg) | 129.9 ± 4.0 | 127.4 ± 2.9 | 134.5 ± 3.0 | 127.2 ± 2.9 | 132.4 ± 3.1 | 125.9 ± 2.1 | 129.9 ± 2.6 | 124.8 ± 3.4 |
| Diastolic BP (mmHg) | 73.2 ± 5.4 | 77.0 ± 2.4 | 83.8 ± 2.6 | 81.9 ± 2.4 | 79.1 ± 1.5 | 79.8 ± 2.3 | 84.4 ± 1.1 | 73.7 ± 1.8 |
| BMI (kg/m2) | 28.3 ± 0.5 | 28.5 ± 0.31 | 28.9 ± 0.7 | 28.4 ± 0.6 | 28.0 ± 0.3 | 27.5 ± 0.3 | 28.9 ± 0.9 | 27.7 ± 1.0 |
| Waist circumference (cm) | 96.9 ± 3.9 | 95.2 ± 3.5 | 101.4 ± 2.9 | 97.1 ± 2.6 | 97.8 ± 4.0 | 97.9 ± 4.9 | 99.1 ± 3.9 | 97.7 ± 3.6 |
